



Release No 163

27 June 2005

Launch of Azilect® commenced in Europe

H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. (Teva) announced today that Azilect®, a once-daily treatment for Parkinson's disease (PD) both as monotherapy in patients with early PD and as an adjunct treatment in moderate to advanced disease, is now available in the United Kingdom. This represents the first launch of Azilect® in a member nation of the European Union following the issuance of a Marketing Authorisation by the European Commission earlier this year. The Marketing Authorisation is valid throughout the European Union and additional launches are planned for the remainder of this year and for 2006. The next launch is expected to take place in Germany within a few weeks time.

Israel Makov, President and CEO of Teva commented: "We are very excited to announce the first European launch of Azilect®. It is extremely fulfilling to successfully develop and launch a new therapy that addresses important unmet needs for PD patients and improve their quality of life". Mr. Makov added, "Today's launch is an important step in the fruitful collaboration with our commercial partner, Lundbeck, and will be the second product to emerge from Teva's close relationship with the world renowned academic research institutes in Israel."

"Azilect® is an effective, simple, and well-tolerated drug for the treatment of Parkinson's disease", says Ole Chrintz, Lundbeck Executive Vice President in charge of sales and marketing in Europe. He continues: "The launch of Azilect® is Lundbeck's third launch of a new, innovative drug in Europe within a period of only three years. Azilect® represents an important contribution to the company's portfolio and long-term strategy of becoming one of the world's leading companies in the field of psychiatry and neurology."

About Azilect®

Azilect® is a novel, potent, second-generation selective irreversible monoamine oxidase type B (MAO-B) inhibitor that blocks the breakdown of dopamine, a substance in the brain needed to facilitate movement.

The development of Azilect® is part of a long-term alliance for co-development in Parkinson's disease and European marketing between Lundbeck and Teva. In the three major European markets, the United Kingdom, Germany and France, Teva and Lundbeck will co-promote Azilect®.



Azilect® was developed by Teva based on research originating from the Technion, Israel Institute of Technology.

About Parkinson's disease

Parkinson's disease is a chronic, progressive, neurodegenerative disorder. The exact cause of Parkinson's disease is unknown, and is believed to be multifactorial, involving genes, environmental factors and aging.

Symptoms include tremors, slowness of movement, stiffness, gait and posture problems. As the disease progresses, symptoms worsen, and the patient will most likely experience motor complications. Ultimately, the disease impairs the patient's ability to function.

The disease afflicts both sexes equally, and it is estimated that close to 4 million people worldwide suffer from Parkinson's disease. The disease typically appears at a late age, affecting about 1% of the population over the age of 65. It is estimated that more than one million people in the EU suffer from Parkinson's disease. In 2004, global sales of drugs to treat Parkinson's disease totalled USD 2.5 billion. Europe accounted for approximately 40% of this revenue.

The content of this release will have no influence on the Lundbeck Group's expectations for the financial result for 2005.

Lundbeck contacts:

Steen Juul Jensen
Vice President
+45 36 43 30 06

Press contact Helle Hedegaard Juhl
Media Relations Officer
+45 36 43 41 68

Investor contact Jacob Tolstrup
Investor Relations Manager
+45 36 43 30 79

Teva contacts:

Dan Suesskind
Chief Financial Officer
Teva Pharmaceutical
Industries Ltd.
(011) 972 2 589 2840

George Barrett
President and CEO
Teva North America
(215) 591 3030

Dorit Meltzer
Director, Investor Relations
Teva Pharmaceutical
Industries Ltd.
(011) 972 3 926 7554



About Teva

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.

About Lundbeck

H. Lundbeck A/S is an international pharmaceutical company engaged in research and development, production, marketing and sales of drugs for the treatment of psychiatric and neurological disorders. In 2004, the company's revenue was DKK 9.7 billion. The number of employees is approx. 5,000. For more information, visit www.lundbeck.com.